博瑞医药2025年中报简析：净利润同比下降83.85%，三费占比上升明显

Core Insights - 博瑞医药's financial performance for the first half of 2025 shows a significant decline in revenue and profit, with total revenue at 537 million yuan, down 18.28% year-on-year, and net profit at 17.17 million yuan, down 83.85% [1] - The company's gross margin decreased to 48.71%, a drop of 11.91% year-on-year, while the net profit margin fell to 0.31%, down 97.53% [1] - The increase in operating expenses, particularly financial, sales, and management costs, has led to a total of 130 million yuan, representing 24.21% of total revenue, an increase of 39.33% year-on-year [1] Financial Performance - Total revenue for Q2 2025 was 288 million yuan, a decrease of 9.16% year-on-year, with net profit for the quarter at 4.21 million yuan, down 90.04% [1] - The company's return on invested capital (ROIC) for the previous year was 3.93%, indicating weak capital returns, with a historical median ROIC of 10.88% since its listing [2] - The cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at 73.67% [2] Business Model and Strategy - 博瑞医药's business relies heavily on R&D and capital expenditures, necessitating careful evaluation of capital projects and their financial viability [2] - The company is considering partnerships for the commercialization of its product BGM0504, with a preference for collaborating with firms that have strong market sales capabilities, such as 华润三九 [4] Market Position and Fund Holdings - The largest fund holding 博瑞医药 is 富国优化增强债券A/B, with a scale of 1.999 billion yuan and a recent net value increase of 0.33% [3] - Several funds have newly entered the top ten holdings of 博瑞医药, indicating growing interest from institutional investors [3]